StockData
Scienture Holdings, Inc. logo

Scienture Holdings, Inc. (SCNX) company profile

SCNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$2.76−0.23 (-7.69%)

Close on Nov 17, 2026Market cap $113.34MP/E –Yield –

About Scienture

Pharmaceutical Preparations, SIC 2834

Scienture Holdings, Inc. is a clinical-stage biopharmaceutical company focused on the development of pharmaceutical products and drug-device combination therapies. The company maintains an active development pipeline comprising multiple drug candidates, including SCN-102, SCN-104, SCN-106, and SCN-107, alongside formulations such as ARBLI losartan oral potassium suspension. Through strategic transactions and licensing arrangements, it advances proprietary product programs aimed at patients and healthcare providers requiring specialized drug treatments.

The company's operations encompass development programs and agreements primarily within the United States. Its commercial activities include relationships with institutional partners, lenders, and healthcare-focused collaborators such as Softell Inc., Micro Merchant Systems, and Superlatus. Scienture Holdings maintains its corporate headquarters at 20 Austin Boulevard in Commack, New York.

Summary of the business section of Scienture's latest annual report, written by StockData.

Company profile

Company

Legal name
Scienture Holdings, Inc.
Headquarters
Commack, NY
Address
20 Austin Blvd. 11725
Phone
(800) 261-0281
Employees
8, Dec 31, 2023
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
CM3 Advisory, San Diego, California

Stock & identifiers

Ticker
SCNX
Former tickers
MEDS until Sep 24, 2024; TRXD until Jul 26, 2021
Exchange
Nasdaq
IPO date
Feb 6, 2014
Shares outstanding
41M, Aug 13, 2026
Public float
$10.20M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-25 reverse, Oct 5, 2026; 1-for-15 reverse, Jun 22, 2023; 1-for-6 reverse, Mar 30, 2020
SEC CIK
1382574
FIGI
BBG000RNLYM7
Share class FIGI
BBG001STZBS0
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Hariharan ShankarCo-CEO & Chairman, Director3,890,383
Mani NarasimhanPresident & Co-CEO, Director2,945,515
Eric Michael SherbChief Financial Officer0

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Mr. Ajjarapu, Dr. Hariharan, and Dr. Mani.
$2.53M$2.26M$64.17K$16–
FY2025
Peo
$2.53M–$64.17K$16–
FY2024$570.58K$650.58K$409.46K$187–
FY2023$628.01K$628.01K$193.65K$87–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsTotalvs. prior year
Surendra Ajjarapu
Former Chairman of the Board, Chief Executive Officer, and Secretary (1)
–$100.00K–$100.00K-82%
Dr. Narasimhan Mani
Current Co-Chief Executive Officer, President, Interim Chief Financial Officer, and Director (4)
$333.17K–$932.00K$1.27M–
Dr. Shankar Hariharan
Current Co-Chief Executive Officer, Executive Chairman, and Director (5)
$233.17K–$932.00K$1.17M–
Eric Sherb
Former Chief Financial Officer (6)
$83.33K–$45.00K$128.33K+56%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“Currently, we have approximately 8 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 19, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 17, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 22, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 8, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 28, 2024Name changeName changed from TRxADE HEALTH, INC to Scienture Holdings, Inc.
Jul 31, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 30, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 15, 2024Late filingNotification of late filing
Apr 2, 2024Late filingNotification of late filing
Mar 6, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 16, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 28, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 15, 2023Late filingNotification of late filing
Sep 14, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 14, 2023Late filingNotification of late filing
Jul 31, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 26, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 7, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 1, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 1, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 14, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 27, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 1, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 28, 2021Name changeName changed from TRXADE GROUP, INC. to TRxADE HEALTH, INC
Jan 27, 2020ListingRegistration of securities on an exchange (Form 8-A)
Oct 28, 2019Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 17, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 5, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 27, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 14, 2014Late filingNotification of late filing

See a number that looks wrong?